Added to YB: 2025-08-11
Pitch date: 2025-08-08
HROW [bullish]
Harrow, Inc.
+35.85%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
Market Cap
$1.6B
Pitch Price
$34.64
Price Target
100.00 (+112%)
Dividend
N/A
EV/EBITDA
38.20
P/E
-324.83
EV/Sales
7.29
Sector
Pharmaceuticals
Category
growth
Show full summary:
Actionable Stock Set-up 7: Harrow Inc (HROW)
HROW: Ophthalmic pharma co w/ rapidly growing VEVYE (8x YOY, targeting $100M+ 2024 rev). Bull: aging population, strong pipeline, strategic acquisitions, mgmt aligned w/ $100 stock target. Bear: heavy debt ($230M), execution risk, high competition. Trading at 6.5x EV/S, 30x NTM P/E but only 8x 2027E.
Read full article (6 min)